Hospitals & Healthcare PR Newswire

Asian Hospital and Healthcare management offers the most advanced strategies in healthcare, the most significant developments in hospital management, provides information on the latest research in healthcare and medical sciences with a special focus on preventive medicine and healthcare.

ACCL Announces Pesticide Warning for Cannabis in North America

Monday, December 05, 2016 PR Newswire

OAKLAND Calif Dec 5 2016 PRNewswire TheAssociation of Commercial Cannabis Laboratories Inc ACCL released a statement today offering information on the continuing concern of pesticide contamination onCannabis ACCL members in several states have detected high levels of various cultivating agents t..

BrainStorm Announces NurOwn® Data to be Highlighted at the 27th International Symposium on ALS/MND

Monday, December 05, 2016 PR Newswire

HACKENSACK NJ and PETACH TIKVAH Israel Dec 5 2016 PRNewswire BrainStorm Cell Therapeutics Inc BCLI a leading developer of adult stem cell technologies for neurodegenerative diseases announced today data from the Companys Phase 2 study of NurOwn in ALS will be highlighted in presentations at the 27..

AOP Orphan and PharmaEssentia Announce Pivotal Phase III Results for Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016

Monday, December 05, 2016 PR Newswire

VIENNA and TAIPEI Taiwan Dec 5 2016 PRNewswire At 12 months of treatment ropeginterferon alfa2b showed noninferiority to hydroxyurea HU in Complete Hematologic Response CHR PROUDPV demonstrated a significantly better safety and tolerability profile of ropeginterferon alfa2b versus HU AOP..

Mission Therapeutics Appoints Colin Goddard as Chairman

Monday, December 05, 2016 PR Newswire

CAMBRIDGE England December 5 2016 PRNewswire Michael Moore Transitions to Deputy Chairman Mission Therapeutics a drug discovery and development company focused on selectively targeting deubiquitylating enzymes DUBs to treat cancer neurodegenerative and other diseases announces that Dr Colin Go..

SystemOne and Daktari Announce Partnership to Bring Connected Diagnostics to Developing World

Sunday, December 04, 2016 PR Newswire

SPRINGFIELD Mass and CAMBRIDGE Mass and CAPE TOWN South Africa Dec 4 2016 PRNewswire SystemOne a company focused on connecting diagnostics and providing connected diagnostics software platforms for the developing world and Daktari Diagnostics a company focused on making Anywhere Care a reality wi..

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate mesylate) in NVAF Patients

Sunday, December 04, 2016 PR Newswire

RIDGEFIELD Conn Dec 4 2016 PRNewswire Boehringer Ingelheim Pharmaceuticals Inc today announced results from a new analysis of the GLORIAAF Registry Program which showed that newly diagnosed nonvalvular atrial fibrillation NVAF patients treated with Pradaxa dabigatran etexilate mesylate had ..

Marapharm Ventures Inc. Pays Off Mortgage on Las Vegas, Nevada Property

Sunday, December 04, 2016 PR Newswire

KELOWNA British Columbia December 4 2016 PRNewswire Marapharm symbols United States OTCQB MRPHF Canada CSE MDM Germany FSE2M0 Marapharm Ventures Inc Marapharm announces that it is paying the Nevada Title Escrow Agent for full payment and discharge of the first mortgage financing on 59 acres..

Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin\'s Lymphoma

Sunday, December 04, 2016 PR Newswire

NORTH CHICAGO Ill Dec 4 2016 PRNewswire AbbVie NYSE ABBV a global biopharmaceutical company today announced encouraging efficacy and safety findings from two separate studies evaluating ibrutinib IMBRUVICA as a combination therapy in two of the most common types of nonHodgkins lymphoma diffuse lar..

Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis

Sunday, December 04, 2016 PR Newswire

CAMBRIDGE Mass Dec 4 2016 PRNewswire Blueprint Medicines CorporationNASDAQ BPMC a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases today announced data from its ongoing Phase 1 trial evaluating BLU285 an investigational medicine for the..

ZIMMER BIOMET (ZBH) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Zimmer Biomet Holdings, Inc.; Encourages all Investors to Contact the Firm for Information

Saturday, December 03, 2016 PR Newswire

SAN DIEGO Dec 3 2016 PRNewswire Johnson Weaver LLP announces that a class action complaint was filed on behalf of purchasers of Zimmer Biomet Holdings Inc NYSE ZBH securities during the period between September 7 2016 through October 31 2016 the Class Period Zimmer Biomet provides musculoskele..

Bioengineering Innovations Show Promise for Improving Treatments and Drug Delivery

Saturday, December 03, 2016 PR Newswire

SAN DIEGO Dec 3 2016 PRNewswireUSNewswire In five studies being presented today during the 58th American Society of Hematology ASH Annual Meeting and Exposition in San Diego researchers are applying advanced biomedical engineering methods to improve the delivery of lifesaving treatments to patient..

After One Dose of Gene Therapy, Hemophilia B Patients Maintain Near-Normal Levels of Clotting Factor

Saturday, December 03, 2016 PR Newswire

SAN DIEGO Dec 3 2016 PRNewswireUSNewswire Researchers are reporting the highest and most sustained levels to date of an essential bloodclotting factor IX in patients with the inherited bleeding disorder hemophilia B After receiving a single dose of an experimental gene therapy in a clinical trial ..

Control Of The Tan Company, MassageLuXe, Xist Fitness, LifeXist And BAM Brands Turned Over To Mark Otter

Saturday, December 03, 2016 PR Newswire

ST LOUIS Dec 3 2016 PRNewswire On April 11 2016 Todd Beckman turned over operational daytoday control of the entire BAM Brands Family to Mark Otter previously aDivision President with the Steak N Shake brand On that date Mr Otter was appointed Chief Operating Officer of BAM Brands Mr Beckman has ..

Sickle Cell Disease Research Shows Progress in Preventing Related Complications and Death

Saturday, December 03, 2016 PR Newswire

SAN DIEGO Dec 3 2016 PRNewswireUSNewswire Sickle cell disease SCD is an inherited chronic disorder characterized by rigid sickleshaped red blood cells that get stuck in veins and block blood flow which can cause severe pain stroke organ failure and complications leading to death Each year approxi..

Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases

Saturday, December 03, 2016 PR Newswire

HOUSTON Dec 3 2016 PRNewswire Pairnomix LLC a genetic research company and member of the PatientEmpowered Precision Medicine Alliance PEPMA recognized by the White House today announced that findings from its first case study of an individualized approach to the identification of candidate therapi..

Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study

Saturday, December 03, 2016 PR Newswire

EAST HANOVER NJ Dec 3 2016 PRNewswire Results from the Phase II SUSTAIN study show that SEG101 crizanlizumab formerly SelG1 an antiPselectin antibody reduced the median annual rate of sickle cellrelated pain crises SCPC by 453 compared to placebo 163 vs 298 p0010 in patients with or without hydrox..

Studies Advance a More Personalized Approach to Treatment

Saturday, December 03, 2016 PR Newswire

SAN DIEGO Dec 3 2016 PRNewswireUSNewswire Studies being presented today during the 58th American Society of Hematology ASH Annual Meeting and Exposition in San Diego aim to bring a more personalized and targeted approach to medicine and empower patients to participate more fully in treatment decis..

St. Jude Memphis Marathon® Weekend raises $10 million for kids battling cancer, other life-threatening diseases at St. Jude Children\'s Research Hospital®

Saturday, December 03, 2016 PR Newswire

MEMPHIS Tenn Dec 3 2016 PRNewswireUSNewswire On Saturday Dec 3 nearly 23000 participants and 40000 spectators from across the US gathered together to celebrate 15 years and running of the St Jude Memphis Marathon Weekend in support of St Jude Childrens Research Hospital Full marathoners Jason H..

Dr. Andre Goy and Cota will present \"Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma\" at 58th American Society of Hematology Annual Meeting & Exposition

Saturday, December 03, 2016 PR Newswire

SAN DIEGO Dec 3 2016 PRNewswire Dr Andre Goy Cota board member and President of the John Theurer Cancer Center will present a new study utilizing realworld evidence to demonstrate the importance of comorbidities on outcomes of patients with mantle cell lymphoma at the 58th American Society of Hem..

IMBRUVICA® (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis and Long-Term RESONATE-2 Follow-up Data at ASH 2016 Show Lasting Efficacy

Saturday, December 03, 2016 PR Newswire

NORTH CHICAGO Ill Dec 3 2016 PRNewswire AbbVie NYSE ABBV a global biopharmaceutical company today announced longterm followup results evaluating up to five years of IMBRUVICA ibrutinib use in patients with chronic lymphocytic leukemiasmall lymphocytic lymphoma CLLSLL In this analysis 89 of treatm..

TOP